Working… Menu

Ultrasonic Energy for Pulmonary Artery Branch Sealing During VATS Lobectomy (VATS PA-ACE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02719717
Recruitment Status : Completed
First Posted : March 25, 2016
Last Update Posted : January 27, 2020
Johnson & Johnson
Information provided by (Responsible Party):
Centre hospitalier de l'Université de Montréal (CHUM)

Brief Summary:

This research program consists of a prospective, multi-institutional Phase 2 trial and an economic cost-effectiveness analysis for the use of ACE+7 in VATS lobectomy/segmentectomy compared to traditional techniques.

It will be left up to the study credentialed surgeon investigator to decide the suitability of PA branches for sealing. This will be decided intra-operatively based on anatomy, vascular dissection and length as well as patient specific factors.

Condition or disease Intervention/treatment Phase
Lung Cancer Device: Harmonic Ace+7 Not Applicable

Detailed Description:

Currently, a minority of anatomic pulmonary resections are being performed by VATS (15%). The technical difficulty and increased actual and perceived danger of VATS lobectomy is related to PA branch manipulation, stapling and division. This is the main limitation for many thoracic surgeons regarding the adoption of VATS lobectomy into their practice. Furthermore, the majority of VATS lobectomies are being performed in high volume, academic medical centers with a resultant disparity in socioeconomic status between those that undergo VATS versus open lobectomy. If we can find a way to decrease the manipulation required by the surgeon on the PA branches, these procedures will be safer, less stressful for the surgeon and therefore more prevalent for anatomical pulmonary resections.

Energy utilization in VATS lobectomy may also be more cost effective than endostaplers. The use of a single device for lymph node dissection, hilar dissection, and PA branch sealing may allow for overall procedural cost savings. There may also be a potential benefit in decreasing overall length of hospital stay due to decrease in chest tube duration secondary to decreased post-operative pleural fluid output following VATS lobectomy when using energy as opposed to cautery for mediastinal lymph node dissection.


  • Systematically evaluate the immediate, short- and medium-term efficacy and safety of PA sealing utilising ACE+7 in a human VATS Lobectomy/Segmentectomy.
  • Understand cost issues related to use of ACE+7 in human VATS Lobectomy/Segmentectomy.

General satisfaction of the surgeon utilizing energy sealing devices compared to standard endostaplers will be assessed using a post-procedural online survey administered by the research team immediately following each procedure.

This multi-institutional, international trial will be important to decrease the bias associated with single center studies and bolster the confidence level of thoracic surgeons in the results of the trial. Study sites have been specifically chosen in the USA, Canada and Europe in order to increase the worldwide generalizability of results.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 150 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prospective, Multi-Center, International Phase 2 Trial of the Use of Ultrasonic Energy for Pulmonary Artery Branch Sealing During VATS Lobectomy
Study Start Date : June 2016
Actual Primary Completion Date : November 9, 2018
Actual Study Completion Date : November 9, 2018

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Harmonic Ace+7
Pulmonary artery sealing with Harmonic Ace+7 in VATS lobectomy
Device: Harmonic Ace+7
Pulmonary artery sealing with Harmonic Ace+7 in VATS lobectomy

Primary Outcome Measures :
  1. For technical success absence of intra-operative bleeding directly related to PA branch ACE+7 sealing on vessels ≤7mm. [ Time Frame: Immediate, intra-operative evaluation ]
    All procedures will be video-recorded for intra-operative assessment of vascular manipulation, vessel sealing and bleeding episodes using high definition thoracoscope video recorder.

Secondary Outcome Measures :
  1. Number of intra-operative transfusions [ Time Frame: Immediate, intra-operative ]
  2. Number of post-operative transfusions [ Time Frame: After the surgery up to 30 days ]
  3. Number of conversion to open surgery [ Time Frame: Immediate, intra-operative ]
  4. Number of intra-operative mortality [ Time Frame: Immediate, intra-operative ]
  5. Length of stay (days) [ Time Frame: After the surgery up to 30 days ]
  6. Chest tube drainage per 24-hour period (mL) [ Time Frame: From the time of surgery to chest tube removal ]
  7. Number of operative take-back for bleeding, source of bleeding [ Time Frame: During the hospitalisation (up to 30 days) ]

Other Outcome Measures:
  1. Number of morbidity and mortality [ Time Frame: From time of discharge to follow up 30 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. ability to consent
  2. > 18 years old
  3. non-hilar tumors
  4. pre-operative imaging (chest CT and PET-CT
  5. invasive mediastinal staging requirement will be based on current American College of Chest Physicians (ACCP) lung cancer staging criteria and will be performed by any of the following tests, in appropriate patients, alone or in combination based on study site preference in accordance with ACCP guidelines - mediastinoscopy, mediastinotomy, VATS, endobronchial ultrasound, endoscopic ultrasound.

Exclusion Criteria:

  1. previous unilateral thoracic surgical procedure or trauma
  2. history of mediastinal or pulmonary irradiation
  3. anticoagulation with inability to stop anticoagulants prior to surgery
  4. systemic vascular disease or vasculitis
  5. uncorrectable coagulopathy
  6. use of systemic steroids or immunosuppressive medication Pulmonary hypertension will not be an exclusion criterion as patients with pulmonary hypertension were shown to have higher bursting pressures following PA sealing in previous studies.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02719717

Layout table for location information
Canada, Quebec
Centre Hospitalier de l'Université de Montréal
Monteal, Quebec, Canada, H2L 4M1
Sponsors and Collaborators
Centre hospitalier de l'Université de Montréal (CHUM)
Johnson & Johnson
Layout table for investigator information
Principal Investigator: Moishe Liberman, MD, PhD Centre hospitalier de l'Université de Montréal (CHUM)
Publications of Results:
Other Publications:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Centre hospitalier de l'Université de Montréal (CHUM) Identifier: NCT02719717    
Other Study ID Numbers: CE 15.302
First Posted: March 25, 2016    Key Record Dates
Last Update Posted: January 27, 2020
Last Verified: March 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Keywords provided by Centre hospitalier de l'Université de Montréal (CHUM):
VATS lobectomy
vascular sealing
pulmonary artery